Filtered By:
Specialty: Drugs & Pharmacology
Nutrition: Calcium
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 116 results found since Jan 2013.
Iptakalim improves cerebral microcirculation in mice after ischemic stroke by inhibiting pericyte contraction
In this study we investigated the impacts of iptakalim on pericytes contraction in stroke. Mice were subjected to cerebral artery occlusion (MCAO), then administered iptakalim (10 mg/kg, ip). We showed that iptakalim administration significantly promoted recovery of cerebral blood flow after cerebral ischemia and reperfusion. Furthermore, we found that iptakalim significantly inhibited pericytes contraction, decreased the number of obstructed capillaries, and improved cerebral microcirculation. Using a collagen gel contraction assay, we demonstrated that cultured pericytes subjected to oxygen-glucose deprivation (OGD) cons...
Source: Acta Pharmacologica Sinica - October 26, 2021 Category: Drugs & Pharmacology Authors: Ruo-Bing Guo Yin-Feng Dong Zhi Yin Zhen-Yu Cai Jin Yang Juan Ji Yu-Qin Sun Xin-Xin Huang Teng-Fei Xue Hong Cheng Xi-Qiao Zhou Xiu-Lan Sun Source Type: research
Y-2 reduces oxidative stress and inflammation and improves neurological function of collagenase-induced intracerebral hemorrhage rats
In conclusion, Y-2 sublingual tablets might be a promising therapeutic agent for the treatment of ICH.PMID:34536364 | DOI:10.1016/j.ejphar.2021.174507
Source: European Journal of Pharmacology - September 18, 2021 Category: Drugs & Pharmacology Authors: Yao Hua Limei Zhou Weidong Yang Wenji An Xiaolin Kou Jian Ren Hailang Su Rong Chen Zhengping Zhang Jianjun Zou Zhihong Zhao Source Type: research
Adverse Cardiovascular Outcomes and Antihypertensive treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies (ICAPS)
Clin Pharmacol Ther. 2021 Jul 7. doi: 10.1002/cpt.2355. Online ahead of print.ABSTRACTWe sought to identify genome-wide variants influencing antihypertensive drug response and adverse cardiovascular outcomes, utilizing data from four randomized controlled trials in the International Consortium for Antihypertensive Pharmacogenomics Studies (ICAPS). Genome-wide antihypertensive drug-SNP interaction tests for four drug classes (β-blockers, n=9,195; calcium channel blockers [CCB], n=10,511; thiazide/thiazide-like diuretics, n=3,516; ACE-inhibitors/ARBs, n=2,559) and cardiovascular outcomes (incident myocardial infarction, str...
Source: Clinical Pharmacology and Therapeutics - July 7, 2021 Category: Drugs & Pharmacology Authors: Caitrin W McDonough Helen R Warren John R Jack Alison A Motsinger-Reif Nicole D Armstrong Joshua C Bis John S House Sonal Singh Nihal M El Rouby Yan Gong Joesyf C Mychaleckyj Daniel M Rotroff Oscar R Benavente Mark J Caulfield Alessandrio Doria Carl J Pep Source Type: research
Exploring the Regulatory Mechanism of Hedysarum Multijugum Maxim.-Chuanxiong Rhizoma Compound on HIF-VEGF Pathway and Cerebral Ischemia-Reperfusion Injury ’s Biological Network Based on Systematic Pharmacology
Conclusion: HCC may play a therapeutic role by regulating CIR-related targets, biological processes and signaling pathways found on this study.
Source: Frontiers in Pharmacology - June 25, 2021 Category: Drugs & Pharmacology Source Type: research
Risk of Cardiovascular Conditions in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study
ConclusionsThis large retrospective cohort study showed that chronic hypoparathyroidism was associated with increased risk of incident cardiovascular conditions and arrhythmias. Results should be evaluated in light of limitations inherent to claims database analyses. Further studies are warranted to investigate reasons for these risks and to develop strategies for reducing cardiovascular conditions in patients with chronic hypoparathyroidism.
Source: Advances in Therapy - June 24, 2021 Category: Drugs & Pharmacology Source Type: research
Uncoupling Protein 2 as a pathogenic determinant and therapeutic target in cardiovascular and metabolic diseases
Curr Neuropharmacol. 2021 Apr 20. doi: 10.2174/1570159X19666210421094204. Online ahead of print.ABSTRACTUncoupling protein 2 (UCP2) is a mitochondrial protein that acts as an anion carrier. It is involved in the regulation of several processes including mitochondrial membrane potential, generation of reactive oxygen species within the inner mitochondrial membrane and calcium homeostasis. UCP2 expression can be regulated at different levels: genetic (gene variants), transcriptional [by peroxisome proliferator-activated receptors (PPARs) and microRNAs], and post-translational. Experimental evidence indicates that activation ...
Source: Current Neuropharmacology - April 22, 2021 Category: Drugs & Pharmacology Authors: Rosita Stanzione Maurizio Forte Maria Cotugno Franca Bianchi Simona Marchitti Carla Letizia Busceti Francesco Fornai Speranza Rubattu Source Type: research
